Your browser doesn't support javascript.
loading
Computed tomography urography with corticomedullary phase can exclude urinary bladder cancer with high accuracy.
Abuhasanein, Suleiman; Hansen, Carl; Vojinovic, Dragan; Jahnson, Staffan; Leonhardt, Henrik; Kjölhede, Henrik.
Afiliação
  • Abuhasanein S; Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 413 90, Göteborg, Sweden. suleiman.abuhasanein@gu.se.
  • Hansen C; Department of Surgery, Urology Section, NU Hospital Group, Uddevalla, Region Västra Götaland, Sweden. suleiman.abuhasanein@gu.se.
  • Vojinovic D; Department of Radiology, NU Hospital Group, Uddevalla, Region Västra Götaland, Sweden.
  • Jahnson S; Department of Radiology, NU Hospital Group, Uddevalla, Region Västra Götaland, Sweden.
  • Leonhardt H; Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
  • Kjölhede H; Department of Radiology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
BMC Urol ; 22(1): 60, 2022 Apr 12.
Article em En | MEDLINE | ID: mdl-35413901
BACKGROUND: To evaluate the diagnostic accuracy of computed tomography-urography (CTU) to rule out urinary bladder cancer (UBC) and whether patients thereby could omit cystoscopy. METHODS: All patients evaluated for macroscopic hematuria with CTU with cortico-medullary phase (CMP) and cystoscopy at our institute between 1st November 2016 and 31st December 2019 were included. From this study cohort a study group consisting of all UBC patients and a control group of 113 patients randomly selected from all patients in the study cohort without UBC. Two radiologists blinded to all clinical data reviewed the CTUs independently. CTUs were categorized as positive, negative or indeterminate. Diagnostic accuracy and proportion of potential omittable cystoscopies were calculated for the study cohort by generalizing the results from the study group. RESULTS: The study cohort consisted of 2195 patients, 297 of which were in the study group (UBC group, n = 207 and control group, n = 90). Inter-rater reliability was high (κ 0.84). Evaluation of CTUs showed that 174 patients were assesessed as positive (showing UBC), 46 patients as indeterminate (not showing UBC but with limited quality of CTU), and 77 patients as negative (not showing UBC with good quality of CTU). False negative rate was 0.07 (95%, CI 0.04-0.12), false positive rate was 0.01 (95% CI 0.0-0.07) and negative predictive value was 0.99 (95% CI 0.92-1.0). The area under the curve was 0.93 (95% CI 0.90-0.96). Only 2.9% (3/102) with high-risk tumors and 11% (12/105) with low- or intermediate-risk tumors had a false negative CTU. Cystoscopy could potentially have been omitted in 57% (1260/2195) of all evaluations. CONCLUSIONS: CTU with CMP can exclude UBC with high accuracy. In case of negative CTU, it might be reasonable to omit cystoscopy, but future confirmative studies with possibly refined technique are needed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: BMC Urol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: BMC Urol Ano de publicação: 2022 Tipo de documento: Article